Long-term benefit from high-dose ifosfamide in sarcoma depends on sustained prior control and timely intervention: a machine learning analysis
HD-IFO provides durable disease control in selected sarcoma patients, particularly those with sustained prior tumor control and intervention prior to progression.
Authors
- Nina-Sophie Schmidt-Hegemann (ORCID: https://orcid.org/0000-0002-2091-3603)
- Alexander Klein (ORCID: https://orcid.org/0000-0002-5562-9872)
- Dorit Di Gioia
- Vindi Jurinović
- Markus Albertsmeier (ORCID: https://orcid.org/0000-0002-5028-5062)
- Sinan E Güler
- Michael Hoberger
- Michael Völkl
- Michael von Bergwelt-Baildon
- Lars H. Lindner
- Wolfgang G. Kunz
- Hans Roland Dürr
- Luc M. Berclaz
- Anton Burkhard-Meier
- Romy L. Zuber
Institutions
- German Cancer Research Center (DE)
- LMU Klinikum (DE)
- Zimmer Biomet (Germany) (DE)
- Centre de Coopération Universitaire Franco-Bavarois (DE)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1007/s00432-025-06410-8
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00